Listed

Aquestive Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2025

Filed with the SEC on Aug 11, 2025 and accepted by EDGAR at Aug 11, 2025, 16:11 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-04-01 to 2025-06-30$10.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2025-01-01 to 2025-06-30$18.7mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2025-04-01 to 2025-06-30$4.6mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2025-01-01 to 2025-06-30$8.2mus-gaap:CostOfGoodsAndServicesSold
Research and development3 months2025-04-01 to 2025-06-30$4.1mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2025-01-01 to 2025-06-30$9.5mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2025-04-01 to 2025-06-30$12.7mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2025-01-01 to 2025-06-30$31.8mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2025-04-01 to 2025-06-30−$11.4mus-gaap:OperatingIncomeLoss
Operating income6 months2025-01-01 to 2025-06-30−$30.7mus-gaap:OperatingIncomeLoss
Interest expense3 months2025-04-01 to 2025-06-30$2.8mus-gaap:InterestExpenseNonoperating
Interest expense6 months2025-01-01 to 2025-06-30$5.6mus-gaap:InterestExpenseNonoperating
Income tax3 months2025-04-01 to 2025-06-30$0us-gaap:IncomeTaxExpenseBenefit
Income tax6 months2025-01-01 to 2025-06-30$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-04-01 to 2025-06-30−$13.5mus-gaap:NetIncomeLoss
Net income6 months2025-01-01 to 2025-06-30−$36.5mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-04-01 to 2025-06-30−$0.14us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2025-01-01 to 2025-06-30−$0.37us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-04-01 to 2025-06-30−$0.14us-gaap:EarningsPerShareBasic
Basic EPS6 months2025-01-01 to 2025-06-30−$0.37us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-04-01 to 2025-06-3099,326,701 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2025-01-01 to 2025-06-3097,422,458 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2025-01-01 to 2025-06-30−$31.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2025-01-01 to 2025-06-30$242.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2025-06-30$60.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-06-30$81.7mus-gaap:AssetsCurrent
Total assetsAt period end2025-06-30$93.7mus-gaap:Assets
Current liabilitiesAt period end2025-06-30$23.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-06-30$166.3mus-gaap:Liabilities
Long-term debtAt period end2025-06-30$45.0mus-gaap:LongTermDebt
Shareholders' equityAt period end2025-06-30−$72.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001398733-25-000013. Last ingested by Listed: Nov 13, 2026, 16:06 ET. Listed shows no prices and gives no investment advice.